KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) Cost of Revenue (2019 - 2025)

Historic Cost of Revenue for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $83.5 million.

  • GoodRx Holdings' Cost of Revenue fell 704.93% to $83.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $346.8 million, marking a year-over-year decrease of 552.07%. This contributed to the annual value of $367.1 million for FY2024, which is 755.46% up from last year.
  • Per GoodRx Holdings' latest filing, its Cost of Revenue stood at $83.5 million for Q3 2025, which was down 704.93% from $84.9 million recorded in Q2 2025.
  • GoodRx Holdings' Cost of Revenue's 5-year high stood at $106.5 million during Q4 2021, with a 5-year trough of $77.4 million in Q2 2023.
  • Over the past 5 years, GoodRx Holdings' median Cost of Revenue value was $89.9 million (recorded in 2024), while the average stood at $88.9 million.
  • In the last 5 years, GoodRx Holdings' Cost of Revenue surged by 7022.53% in 2021 and then crashed by 2099.99% in 2022.
  • GoodRx Holdings' Cost of Revenue (Quarter) stood at $106.5 million in 2021, then decreased by 21.0% to $84.1 million in 2022, then grew by 11.44% to $93.8 million in 2023, then increased by 0.08% to $93.8 million in 2024, then decreased by 10.97% to $83.5 million in 2025.
  • Its last three reported values are $83.5 million in Q3 2025, $84.9 million for Q2 2025, and $84.5 million during Q1 2025.